| 517.1 | V08AB02 | iohexol (koncentrace 180 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 231,11 | K |
| 517.2 | V08AB02 | iohexol (koncentrace 240 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 199,40 | K |
| 04337 | OMNIPAQUE 240 | inj 25x20ml | NYI | N |
| 517.3 | V08AB02 | iohexol (koncentrace 240 mg l/ml, do 15 ml v jedné ampuli včetně) | parent. | 10 | ML | 276,10 | K |
| 517.4 | V08AB02 | iohexol (koncentrace 240 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 153,38 | K |
| 517.5 | V08AB02 | iohexol (koncentrace 300 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 231,80 | K |
| 69029 | OMNIPAQUE 300 | inj 10x40ml-pp | NYI | N |
| 517.6 | V08AB02 | iohexol (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 320,96 | K |
| 517.7 | V08AB02 | iohexol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 178,32 | K |
| 517.8 | V08AB02 | iohexol (koncentrace 350 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 258,97 | K |
| 69028 | OMNIPAQUE 350 | inj 10x40ml-pp | NYI | N |
| 517.9 | V08AB02 | iohexol (koncentrace 350 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 199,21 | K |
| 517.10 | V08AB03 | kyselina ioxagliková (koncentrace 320 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 236,91 | K |
| 517.11 | V08AB03 | kyselina ioxagliková (koncentrace 320 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 186,90 | K |
| 517.12 | V08AB04 | iopamidol (koncentrace 200 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 242,54 | K |
| 517.13 | V08AB04 | iopamidol (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 299,78 | K |
| 71993 | IOPAMIRO 300 | inj 5x10ml | BCC | I |
| 517.14 | V08AB04 | iopamidol (koncentrace 300 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 185,92 | K |
| 517.15 | V08AB04 | iopamidol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 169,67 | K |
| 71994 | IOPAMIRO 300 | inj 1x100ml | BCC | I |
| 517.16 | V08AB04 | iopamidol (koncentrace 370 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 365,98 | K |
| 517.17 | V08AB04 | iopamidol (koncentrace 370 mg l/ml, nad 15 do 30 ml v jedné ampuli včetně) | parent. | 10 | ML | 224,93 | K |
| 517.18 | V08AB04 | iopamidol (koncentrace 370 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 181,10 | K |
| 71988 | IOPAMIRO 370 | inj 1x100ml | BCC | I |
| 517.19 | V08AB05 | iopromid (koncentrace 240 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 153,38 | K |
| 517.20 | V08AB05 | iopromid (koncentrace 300 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 231,80 | K |
| 77024 | ULTRAVIST-300 | inj 10x20ml | SAG | D |
| 517.21 | V08AB05 | iopromid (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 178,32 | K |
| 517.22 | V08AB05 | iopromid (koncentrace 370 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 207,38 | K |
| 517.23 | V08AB06 | iotrolan (koncentrace 240 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 429,71 | KIP |
| 517.24 | V08AB06 | iotrolan (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 534,28 | KIP |
| 517.25 | V08AB07 | ioversol (koncentrace 160 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 119,48 | K |
| 68772 | OPTIRAY 160 | inj 10x50ml | MME | D |
| 517.26 | V08AB07 | ioversol (koncentrace 240 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 153,38 | K |
| 68922 | OPTIRAY 240 | inj 10x100ml | MME | D |
| 98298 | OPTIRAY 240 | inj 10x50ml | MME | D |
| 66210 | OPTIRAY 240 | inj 10x100ml(typa) | MME | CND |
| 66209 | OPTIRAY 240 | inj 10x100ml(typ a) | MME | USA |
| 517.27 | V08AB07 | ioversol (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 320,96 | K |
| 92365 | OPTIRAY 300 | inj 10x10ml | MME | D |
| 517.28 | V08AB07 | ioversol (koncentrace 300 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 231,80 | K |
| 68923 | OPTIRAY 300 | inj 10x20ml | MME | D |
| 66211 | OPTIRAY 300 | inj 10x20ml(typ a) | MME | USA |
| 66212 | OPTIRAY 300 | inj 10x20ml(typ a) | MME | CND |
| 517.29 | V08AB07 | ioversol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 178,32 | K |
| 68850 | OPTIRAY 300 | inj 10x50ml | MME | D |
| 92366 | OPTIRAY 300 | inj 10x75ml | MME | D |
| 92369 | OPTIRAY 300 | inj 10x200ml | MME | D |
| 92367 | OPTIRAY 300 | inj 10x100ml | MME | D |
| 92368 | OPTIRAY 300 | inj 10x150ml | MME | D |
| 517.30 | V08AB07 | ioversol (koncentrace 320 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 186,90 | K |
| 68773 | OPTIRAY 320 | inj 10x50ml | MME | D |
| 517.31 | V08AB07 | ioversol (koncentrace 350 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 258,97 | K |
| 66230 | OPTIRAY 350 | inj 10x30ml(typ a) | MME | CND |
| 66229 | OPTIRAY 350 | inj 10x30ml(typ a) | MME | USA |
| 92370 OPTIRAY 350 | inj 10x30ml | MME | D |
| 517.32 | V08AB07 | ioversol (koncentrace 350 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 199,21 | K |
| 68851 | OPTIRAY 350 | inj 10x50ml | MME | D |
| 68925 | OPTIRAY 350 | inj 10x100ml | MME | D |
| 92371 | OPTIRAY 350 | inj 10x200ml | MME | D |
| 517.33 | V08AB09 | iodixanol (koncentrace 150 mg l/ml, od 50 ml v jedné ampuli) | parent. | 10 | ML | 215,46 | K |
| 45115 | VISIPAQUE 150MG l/ML | inj 6x200ml | NRI | IRL |
| 45114 | VISIPAQUE 150MG l/ML | inj 10x50ml | NRI | IRL |
| 84340 | VISIPAQUE 150MG l/ML | inj 6x200ml | NYI | N |
| 84339 | VISIPAQUE 150MG l/ML | inj 10x50ml | NYI | N |
| 517.34 | V08AB09 | iodixanol (koncentrace 270 mg l/ml, do 30 ml včetně v jedné ampuli ) | parent. | 10 | ML | 336,60 | K |
| 84341 | VISIPAQUE 270MG l/ML | inj 10x20ml | NYI | N |
| 45118 | VISIPAQUE 270MG l/ML | inj 10x20ml | NRI | IRL |
| 517.35 | V08AB09 | iodixanol (koncentrace 270 mg l/ml, od 50 ml v jedné ampuli) | parent. | 10 | ML | 282,14 | K |
| 45120 | VISIPAQUE 270MG l/ML | inj 10x100ml | NRI | IRL |
| 45121 | VISIPAQUE 270MG l/ML | inj 6x200ml | NRI | IRL |
| 45119 | VISIPAQUE 270MG l/ML | inj 10x50ml | NRI | IRL |
| 84344 | VISIPAQUE 270MG l/ML | inj 6x200ml | NYI | N |
| 84343 | VISIPAQUE 270MG l/ML | inj 10x100ml | NYI | N |
| 84342 | VISIPAQUE 270MG l/ML | inj 10x50ml | NYI | N |
| 517.36 | V08AB09 | iodixanol (koncentrace 320 mg l/ml, do 30 ml včetně v jedné ampuli) | parent. | 10 | ML | 357,46 | K |
| 45122 | VISIPAQUE 320MG l/ML | inj 10x20ml | NRI | IRL |
| 84345 | VISIPAQUE 320MG l/ML | inj 10x20ml | NYI | N |
| 517.37 | V08AB09 | iodixanol (koncentrace 320 mg l/ml, od 50 ml v jedné ampuli) | parent. | 10 | ML | 287,25 | K |
| 84347 | VISIPAQUE 320MG l/ML | inj 10x100ml | NYI | N |
| 84346 | VISIPAQUE 320MG l/ML | inj 10x50ml | NYI | N |
| 84348 | VISIPAQUE 320MG l/ML | inj 6x200ml | NYI | N |
| 45124 | VISIPAQUE 320MG l/ML | inj 10x100ml | NRI | IRL |
| 45123 | VISIPAQUE 320MG l/ML | inj 10x50ml | NRI | IRL |
| 45125 | VISIPAQUE 320MG l/ML | inj 6x200ml | NRI | IRL |
| 517.38 | V08AB10 | iomeprol (koncentrace 150 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 115,90 | K |
| 517.39 | V08AB10 | iomeprol (koncentrace 200 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 137,12 | K |
| 517.40 | V08AB10 | iomeprol (koncentrace 250 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 157,46 | K |
| 517.41 | V08AB10 | iomeprol (koncentrace 300 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 231,80 | K |
| 517.42 | V08AB10 | iomeprol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 178,32 | K |
| 517.43 | V08AB10 | iomeprol (koncentrace 350 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 258,97 | K |
| 517.44 | V08AB10 | iomeprol (koncentrace 350 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 199,21 | K |
| 517.45 | V08AB10 | iomeprol (koncentrace 400 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 285,86 | K |
| 517.46 | V08AB10 | iomeprol (koncentrace 400 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 219,87 | K |
| 518 | V08AC | rozpustné hepatotropní RTG kontrastní látky | parent. | K |
|---|
| 518.1 | V08AC | kyselina iodoxamová (koncentrace 183 mg l/ml) | parent. | 10 | ML | 74,25 | K |
| 518.2 | V08AC | kyselina iodoxamová (koncentrace 45 mg l/ml) | parent. | 10 | ML | 37,39 | K |
| 518.3 | V08AC04 | adipiodon | parent. | 10 | ML | 39,35 | K |
| 519 | V08AD | nerozpustné RTG kontrastní látky | parent. | K |
|---|
| 519.1 | V08AD | iopydol + iopyron | parent. | 10 | ML | 300,70 | K |
| 519.2 | V08AD01 | ethylestery jodovaných mastných kyselin | parent. | 10 | ML | 462,54 | K |
| 03552 | LIPIODOL ULTRA-FLUID | inj 5x5ml | BGL | D |
| 520 | V08BA | RTG kontrastní přípravky obsahující síran barnatý | p.o. | K |
|---|
| 520.1 | V08BA01 | síran barnatý | p.o. | 100 | GM | 33,29 | K |
| 94370 | PRONTOBARIO 60% | sus 1x5lt | BCC | I |
| 59062 | MICROPAQUE | sus 1x2000ml | DEF | F |
| 520.2 | V08BA01 | síran barnatý (lékové formy pro CT) | p.o. | 7.5 | GM | 150,30 | K |
| 46675 | MICROPAQUE CT | sus 1x2000ml/100gm | DEF | F |
| 520.3 | V08BA01 | síran barnatý (lékové formy kolon) | p.o. | 100 | GM | 45,00 | K |
| 46673 | MICROPAQUE COLON | plv 1x800gm | DEF | F |
| 520.4 | V08BA01 | síran barnatý (lékové formy pasty) | p.o. | 100 | GM | 94,58 | K |
| 520.5 | V08BA01 | síran barnatý (lékové formy HD) | p.o. | 100 | GM | 38,08 | K |
| 59063 | MICROPAQUE H.D. ORAL | plv 1x416gm | DEF | F |
| 521 | V08CA | paramagnetické kontrastní látky | parent. | K |
|---|
| 521.1 | V08CA | dimeglumin gadobenat (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1978,62 | K |
| 521.2 | V08CA | dimeglumin gadobenat ( nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1840,15 | K |
| 521.3 | V08CA | Gadobutrol | parent. | 10 | ML | 1840,15 | K |
| 521.4 | V08CA01 | dimeglumin gadopentetat (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1978,62 | K |
| 44487 | MAGNEVIST | inj 5x10ml | SAG | D |
| 75660 | MAGNEVIST | inj 1x10ml | SAG | D |
| 75659 | MAGNEVIST | inj 1x5ml | SAG | D |
| 521.5 | V08CA01 | dimeglumin gadopentetat (nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1840,15 | K |
| 96352 | MAGNEVIST | inj 1x20ml | SAG | D |
| 521.6 | V08CA03 | gadodiamid (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1978,62 | K |
| 521.7 | V08CA03 | gadodiamid (nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1840,15 | K |
| 521.8 | V08CA04 | gadoteridol (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1978,62 | K |
| 521.9 | V08CA04 | gadoteridol (nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1840,15 | K |
| 521.10 | V08CA05 | Manganfodipir | parent. | 10 | ML | 1249,06 | K |
| 49538 | TESLASCAN | sol 1x50ml | NYI | N |
| 49539 | TESLASCAN | sol 10x50ml | NYI | N |
| 521.11 | V08DA01 | mikročástice albuminu s oktafluoropanem | parent. | 1 | DF | 2857,50 | H |
| 521.12 | V08DA02 | mikročástice galaktózy | parent. | 1 | GM | 1142,99 | H |
| 43916 | LEVOVIST | inj sic 1x4gm+solv. | SAG | D |